RECRUITING

A Study of Lung Cancer Screening in People With Unexplained Weight Loss

Conditions

Lung Cancer Screening ctDNA analysis Low dose computed tomography (CT)

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The researchers are doing this study to see if people with unexplained weight loss who have lung cancer screening are more likely to have or develop lung cancer than people without unexplained weight loss. The lung cancer screening will involve use of low-dose computed tomography (LDCT), a CT scan that gives off very low doses of radiation and can make detailed pictures of the lungs to help find tumors. The study researchers will also analyze participants' blood samples to determine if blood testing can be used to help to diagnose lung cancer.

Official Title

Enrichment of Lung Cancer Screening Through Unexplained Weight Loss (UWL) to Stage Shift and Improve Survival

Quick Facts

Study Start:2024-12-02

Study Completion:2026-12

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06717334

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:50 Years to 80 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:Yes

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Eligible for American Cancer Society lung cancer screening, as follows: * Age 50-80 years old * At least 20-pack year history of smoking * Medical record documentation of weight in an electronic medical record at enrollment and 12 months prior to enrollment, +/- 3 months. * Weight loss of 3-10%, defined as UWL, in the prior 12 months +/- 3 months prior to enrollment, that cannot be attributed to an underlying medical condition at the discretion of the enrolling investigator * Life expectancy greater than 1 year, per assessment of the treating clinician.	* Currently pregnant or trying to become pregnant via self-report * Prior history of recent CT scan of the chest either through LDCT screening or with a scan of the chest (standard, not LDCT) performed within the past 12 months * Prior history of NSCLC * Currently undergoing or referred for diagnostic evaluation due to clinical suspicion for malignancy (e.g., referred to a medical or surgical oncologist, or scheduled for biopsy on the basis of a suspicious imaging abnormality). * Patients with a germline pathogenic genetic variant who have undergone whole body MRI within the past 12 months * Unable to comply with study procedures

Inclusion Criteria

Exclusion Criteria

* Eligible for American Cancer Society lung cancer screening, as follows:
* Age 50-80 years old
* At least 20-pack year history of smoking
* Medical record documentation of weight in an electronic medical record at enrollment and 12 months prior to enrollment, +/- 3 months.
* Weight loss of 3-10%, defined as UWL, in the prior 12 months +/- 3 months prior to enrollment, that cannot be attributed to an underlying medical condition at the discretion of the enrolling investigator
* Life expectancy greater than 1 year, per assessment of the treating clinician.

* Currently pregnant or trying to become pregnant via self-report
* Prior history of recent CT scan of the chest either through LDCT screening or with a scan of the chest (standard, not LDCT) performed within the past 12 months
* Prior history of NSCLC
* Currently undergoing or referred for diagnostic evaluation due to clinical suspicion for malignancy (e.g., referred to a medical or surgical oncologist, or scheduled for biopsy on the basis of a suspicious imaging abnormality).
* Patients with a germline pathogenic genetic variant who have undergone whole body MRI within the past 12 months
* Unable to comply with study procedures

Contacts and Locations

Study Contact

Daniel Gomez, MD

CONTACT

212-639-2087

gomezd@mskcc.org

Bernard Park, MD

CONTACT

646-888-3346

Principal Investigator

Daniel Gomez, MD

PRINCIPAL_INVESTIGATOR

Memorial Sloan Kettering Cancer Center

Study Locations (Sites)

Memorial Sloan Kettering at Basking Ridge (All Protocol Activities)

Basking Ridge, New Jersey, 07920

United States

Memorial Sloan Kettering Monmouth (All Protocol Activities)

Middletown, New Jersey, 07748

United States

Memorial Sloan Kettering Bergen (All Protocol Activities)

Montvale, New Jersey, 07645

United States

Montefiore Health Systems (Montefiore Medical Center)

Bronx, New York, 10467

United States

Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities)

Commack, New York, 11725

United States

Memorial Sloan Kettering Westchester (All Protocol Activities)

Harrison, New York, 10604

United States

Memorial Sloan Kettering Cancer Center (All Protocol Activities)

New York, New York, 10065

United States

Memorial Sloan Kettering Nassau (All Protocol Activities)

Uniondale, New York, 11553

United States

Collaborators and Investigators

Sponsor: Memorial Sloan Kettering Cancer Center

Daniel Gomez, MD, PRINCIPAL_INVESTIGATOR, Memorial Sloan Kettering Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-12-02

Study Completion Date2026-12

Study Record Updates

Study Start Date2024-12-02

Study Completion Date2026-12

Terms related to this study

Keywords Provided by Researchers

ctDNA analysis
Low dose computed tomography (CT)

Additional Relevant MeSH Terms

Lung Cancer Screening